STOCK TITAN

Autolus Therapeutics plc - AUTL STOCK NEWS

Welcome to our dedicated news page for Autolus Therapeutics plc (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Autolus Therapeutics plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Autolus Therapeutics plc's position in the market.

Rhea-AI Summary
Autolus Therapeutics plc announced its operational and financial results for the quarter ended September 30, 2023. The company is on track to submit a Biologics License Application (BLA) for its potentially transformational treatment, Obe-cel, for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia (ALL) to the US FDA by the end of 2023. The company also provided updates on clinical data, commercial manufacturing facility progress, and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.92%
Tags
-
Rhea-AI Summary
Autolus Therapeutics to hold virtual event to discuss CAR T strategy in autoimmune diseases and Phase 1 study in systemic lupus erythematosus (SLE)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
conferences
-
Rhea-AI Summary
Autolus Therapeutics to release Q3 2023 financial results and operational highlights
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
conferences earnings
Rhea-AI Summary
Autolus Therapeutics to release Q3 2023 financial results and operational highlights
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
conferences earnings
-
Rhea-AI Summary
AUTO1/22 shows promise in preventing antigen evasion in pediatric B-ALL
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
none
-
Rhea-AI Summary
Autolus Therapeutics announces operational and financial results for Q2 2023, including progress on obe-cel treatment for B-cell Acute Lymphoblastic Leukemia (ALL) and plans for commercial launch in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
Rhea-AI Summary
Autolus Therapeutics announces publication on enhancing CAR T cell therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Autolus Therapeutics plc

Nasdaq:AUTL

AUTL Rankings

AUTL Stock Data

1.29B
91.18M
18.04%
53.51%
1.57%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United Kingdom
58 Wood Lane

About AUTL

autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.